Evidence map›Paper›PMID 29389170›Full record

Trial reportExperimental and clinical psychopharmacology2018

Effects of varenicline on cognitive performance in heavy drinkers: Dose-response effects and associations with drinking outcomes.

Walter Roberts, Sherry A McKee

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Experimental and clinical psychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Efficacy of Varenicline in the Treatment of Alcohol Dependence: An Updated Meta-Analysis and Meta-Regression.International journal of environmental research and public health · 2023
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Brain Structure and Function in Recovery.Alcohol research : current reviews · 2020
    Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Walter RobertsDepartment of Psychiatry, Yale School of Medicine.ORCID 0000-0001-6817-884X
Sherry A McKeeDepartment of Psychiatry, Yale School of Medicine.
Yale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale University Clinical and Translational Science Award ProgramUL1TR000142 · NCATS · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2012 to 2015
$31.8M
Research Training Fellowship in Substance use and Addiction (RTFSA)T32DA007238 · NIDA · YALE UNIVERSITY · PI BRIAN D. KILUK, ISMENE L. PETRAKIS · 1988 to 2026
$5.7M
Does Guanfacine, an alpha2 adrenergic agonist, attenuate stress-induced drinking?R01AA022285 · NIAAA · YALE UNIVERSITY · PI MCKEE, SHERRY ANN · 2014 to 2017
$1.5M
Dose ranging study of varenicline on human alcohol self-administration behaviorR01AA017976 · NIAAA · YALE UNIVERSITY · PI MCKEE, SHERRY ANN · 2009 to 2011
$1.0M
NCATS NIH HHS UL1 TR000142NCATS NIH HHS UL1 TR001863NIAAA NIH HHS R01 AA017976NIAAA NIH HHS R01 AA022285NIDA NIH HHS T32 DA007238NIH HHSPfizer
6 · The paper itself

Abstract

Varenicline reduces drinking in people with alcohol use disorder, but little is known about the mechanisms underlying this effect. Varenicline targets α4β2 and α7 nicotinic acetylcholine receptors, which are associated with several cognitive functions such as working memory. Varenicline may improve drinking outcomes by enhancing cognitive functioning. The current manuscript reports on cognitive outcomes from a placebo-controlled, double-blind human laboratory experiment examining the effects of varenicline on drinking behavior (Verplaetse et al., 2016a). Participants were 55 adult heavy drinkers who met criteria for an alcohol use disorder. They were randomized to receive varenicline (1 mg/day, 2 mg/day) or placebo. They completed a baseline assessment of cognitive functioning (i.e., digits backward task, continuous performance task) before starting medication. After a medication titration period, they attended a laboratory session (post medication Day 8) where they completed the cognitive assessment battery and an alcohol-primed ad libitum drinking task. Blood was collected to measure plasma varenicline levels. Varenicline produced dose-dependent improvements in working memory. Although there was no significant effect of oral varenicline dose on response time on the continuous performance task, participants with higher levels of plasma varenicline showed greater improvement of reaction time (RT). Among participants receiving 2 mg/day varenicline, larger improvements in working memory were associated less drinking, although mediation analyses did not find a significant indirect effect. These findings suggest that varenicline can improve working memory above baseline levels in heavy drinkers. Varenicline may reduce rates of alcohol use by improving working memory. (PsycINFO Database Record

Indexed as

AdultAlcohol DrinkingAlcoholismCognitionDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansMaleMemory, Short-TermNicotinic AgonistsReaction TimeVareniclineYoung AdultNicotinic AgonistsVarenicline

Identifiers

PMID29389170
PMCPMC5797996
OpenAlexW2789275010

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.